Polyglutamine toxicity in non-neuronal cells
- PMID: 20231860
- PMCID: PMC3074229
- DOI: 10.1038/cr.2010.32
Polyglutamine toxicity in non-neuronal cells
Abstract
The neurodegenerative polyglutamine diseases are caused by an expansion of unstable polyglutamine repeats in various disease proteins. Although these mutant proteins are expressed ubiquitously in neuronal and non-neuronal cells, they cause selective degeneration of specific neuronal populations. Recently, increasing evidence shows that polyglutamine disease proteins also affect non-neuronal cells. However, it remains unclear how the expression of polyglutamine proteins in non-neuronal cells contributes to the course of the polyglutamine diseases. Here, we discuss recent findings about the expression of mutant polyglutamine proteins in non-neuronal cells and their influence on neurological symptoms. Understanding the contribution of non-neuronal polyglutamine proteins to disease progression will help elucidate disease mechanisms and also help in the development of new treatment options.
Conflict of interest statement
Conflict of Interest: None declared.
Similar articles
-
The Expanding Clinical Universe of Polyglutamine Disease.Neuroscientist. 2019 Oct;25(5):512-520. doi: 10.1177/1073858418822993. Epub 2019 Jan 7. Neuroscientist. 2019. PMID: 30614396 Free PMC article. Review.
-
[The advances in research on phosphorylation of polyglutamine disease].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Aug;25(4):414-7. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008. PMID: 18683139 Review. Chinese.
-
Role of proteolysis in polyglutamine disorders.J Neurosci Res. 2003 Nov 1;74(3):406-16. doi: 10.1002/jnr.10746. J Neurosci Res. 2003. PMID: 14598317 Review.
-
Polyglutamine disease: recent advances in the neuropathology of dentatorubral-pallidoluysian atrophy.Neuropathology. 2006 Aug;26(4):346-51. doi: 10.1111/j.1440-1789.2006.00670.x. Neuropathology. 2006. PMID: 16961072 Review.
-
Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.FEBS Lett. 2013 Jun 27;587(13):1997-2007. doi: 10.1016/j.febslet.2013.05.022. Epub 2013 May 15. FEBS Lett. 2013. PMID: 23684638 Review.
Cited by
-
Effects of flanking sequences and cellular context on subcellular behavior and pathology of mutant HTT.Hum Mol Genet. 2020 Mar 13;29(4):674-688. doi: 10.1093/hmg/ddaa001. Hum Mol Genet. 2020. PMID: 31943010 Free PMC article.
-
Drosophila as a potential model to ameliorate mutant Huntington-mediated cardiac amyloidosis.Rare Dis. 2014 Nov 3;2(1):e968003. doi: 10.4161/2167549X.2014.968003. eCollection 2014. Rare Dis. 2014. PMID: 26942103 Free PMC article.
-
Large animal models for Huntington's disease research.Zool Res. 2024 Mar 18;45(2):275-283. doi: 10.24272/j.issn.2095-8137.2023.199. Zool Res. 2024. PMID: 38485497 Free PMC article. Review.
-
Pathogenic Huntingtin aggregates alter actin organization and cellular stiffness resulting in stalled clathrin-mediated endocytosis.Elife. 2024 Oct 9;13:e98363. doi: 10.7554/eLife.98363. Elife. 2024. PMID: 39382268 Free PMC article.
-
Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart.PLoS Genet. 2013;9(12):e1004024. doi: 10.1371/journal.pgen.1004024. Epub 2013 Dec 19. PLoS Genet. 2013. PMID: 24367279 Free PMC article.
References
-
- Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000;23:217–247. - PubMed
-
- van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol. 2009;8:765–774. - PubMed
-
- The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources